Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
25
9
2019
medline:
16
7
2020
entrez:
25
9
2019
Statut:
ppublish
Résumé
Increasing evidence suggests that cancer-associated inflammation, as indicated by markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and modified Glasgow Prognostic Score (mGPS), predicts poor outcomes in pancreatic cancer. In this study, the associations between systemic inflammation markers and survival were examined in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) patients who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgical resection. From April 2009 to December 2017, 119 patients diagnosed with BR-PDAC and receiving NACRT followed by radical surgery were included in this retrospective study. The associations between the pre- and post-NACRT NLR, PLR, mGPS, and clinicopathological characteristics, as well as their predictive values for survival outcomes, were analyzed. This study was approved by an institutional review board at Yokohama City University (B180600049). On multivariate analysis with a Cox's proportional hazards regression model, post-NACRT NLR ≥3 (p = 0.040; hazard ratio, 2.24; 95% CI 1.28-3.91) and lymph node metastasis (p = 0.002; hazard ratio, 2.33; 95% CI 1.36-3.99) were significantly associated with shorter overall survival. The median survival time was 22.0 months for patients with post-NACRT NLR ≥3 and 45.0 months for patients with post-NACRT NLR <3 (p = 0.028). The NLR following NACRT might predict survival in BR-PDAC patients. Patients with an elevated post-NACRT NLR or positive lymph node metastasis may be candidates for stronger adjuvant therapies.
Sections du résumé
BACKGROUND
Increasing evidence suggests that cancer-associated inflammation, as indicated by markers such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and modified Glasgow Prognostic Score (mGPS), predicts poor outcomes in pancreatic cancer. In this study, the associations between systemic inflammation markers and survival were examined in borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) patients who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgical resection.
METHODS
From April 2009 to December 2017, 119 patients diagnosed with BR-PDAC and receiving NACRT followed by radical surgery were included in this retrospective study. The associations between the pre- and post-NACRT NLR, PLR, mGPS, and clinicopathological characteristics, as well as their predictive values for survival outcomes, were analyzed. This study was approved by an institutional review board at Yokohama City University (B180600049).
RESULTS
On multivariate analysis with a Cox's proportional hazards regression model, post-NACRT NLR ≥3 (p = 0.040; hazard ratio, 2.24; 95% CI 1.28-3.91) and lymph node metastasis (p = 0.002; hazard ratio, 2.33; 95% CI 1.36-3.99) were significantly associated with shorter overall survival. The median survival time was 22.0 months for patients with post-NACRT NLR ≥3 and 45.0 months for patients with post-NACRT NLR <3 (p = 0.028).
CONCLUSIONS
The NLR following NACRT might predict survival in BR-PDAC patients. Patients with an elevated post-NACRT NLR or positive lymph node metastasis may be candidates for stronger adjuvant therapies.
Identifiants
pubmed: 31549202
doi: 10.1007/s00268-019-05159-9
pii: 10.1007/s00268-019-05159-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3153-3160Références
AJR Am J Roentgenol. 2010 Sep;195(3):W221-8
pubmed: 20729419
BMJ. 2012 Feb 03;344:e454
pubmed: 22306478
Ann Surg Oncol. 2016 Feb;23(2):646-54
pubmed: 26416715
Gastroenterol Res Pract. 2018 Jun 7;2018:9745601
pubmed: 29977290
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
PLoS One. 2017 Mar 14;12(3):e0173955
pubmed: 28291841
J Clin Lab Anal. 2016 Sep;30(5):597-601
pubmed: 26666737
J Surg Oncol. 2015 Nov;112(6):654-7
pubmed: 26437893
Ann Surg Oncol. 2014 Feb;21(2):670-6
pubmed: 24310792
Nat Rev Immunol. 2013 Mar;13(3):159-75
pubmed: 23435331
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Int J Radiat Biol. 1989 Nov;56(5):617-21
pubmed: 2573656
World J Urol. 2016 Jun;34(6):821-7
pubmed: 26449784
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancer. 2012 Dec 1;118(23):5749-56
pubmed: 22605518
World J Surg Oncol. 2015 Sep 30;13:291
pubmed: 26424708
Ann Surg Oncol. 2015 Feb;22(2):670-6
pubmed: 25155401
Med Sci Monit. 2017 Jan 19;23:315-324
pubmed: 28100902
J Surg Oncol. 2017 Sep;116(3):416-426
pubmed: 28608409
Br J Cancer. 2015 Jun 30;113(1):150-8
pubmed: 26022929
J Clin Oncol. 2009 Nov 20;27(33):5513-8
pubmed: 19858379
Radiat Res. 1982 Jan;89(1):38-52
pubmed: 7038741
Exp Ther Med. 2011 Jan;2(1):95-101
pubmed: 22977476
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Am J Surg. 2012 Nov;204(5):580-5
pubmed: 22902100
Br J Surg. 2018 Jul;105(8):946-958
pubmed: 29708592
Endocrine. 2014 Aug;46(3):526-31
pubmed: 24272600
Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):533-9
pubmed: 22116095
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Pancreatology. 2016 Jan-Feb;16(1):28-37
pubmed: 26687001
Angiogenesis. 2003;6(4):283-7
pubmed: 15166496
J Exp Med. 1992 Aug 1;176(2):593-8
pubmed: 1386877
Cancer Biomark. 2015;15(6):899-907
pubmed: 26444485
Clin Appl Thromb Hemost. 2013 Sep;19(5):579
pubmed: 23344995
Ann N Y Acad Sci. 1961 Nov 13;95:839-48
pubmed: 13909294
Clin Transl Oncol. 2014 Mar;16(3):330-5
pubmed: 23860726
Tumour Biol. 2016 Jan;37(1):361-8
pubmed: 26219894
Tumori. 2013 Jul-Aug;99(4):516-22
pubmed: 24326841
Pathologe. 2010 Sep;31(5):331-2
pubmed: 20703480
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Ann Surg Oncol. 2019 Feb;26(2):644-651
pubmed: 30523468
Radiat Res. 1990 May;122(2):155-60
pubmed: 2139973
J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93
pubmed: 25099441
Blood. 1990 Aug 15;76(4):655-63
pubmed: 2200535
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Dig Surg. 2015;32(6):496-503
pubmed: 26544755
Int J Radiat Biol Relat Stud Phys Chem Med. 1983 Feb;43(2):133-40
pubmed: 6600727
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Oncology. 2013;85(1):27-32
pubmed: 23816828